Custom service
Peptide Drugs Blood-brain Barrier Permeability Test Platform
Assess bbb permeability of peptide candidates with in-vitro models
Peptide Drugs Blood-brain Barrier Permeability Test Platform supports programmes that assess BBB permeability of peptide candidates with in-vitro models. In a typical engagement we plan the transwell (MDCK/Boelden-style) transport assays route first, confirm compatibility with PAMPA-BBB screening, and release BBB permeability report with rank comparison on a 4–8 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep transwell (MDCK/Boelden-style) transport assays as the primary option and hold PAMPA-BBB screening in reserve, so that scale-up never depends on an unproven step.
CNS-programme candidate triage
Cyclo(Ala-Val)-style shuttle evaluation
In-vivo brain-exposure studies
Targets with no assayable readout and no purified protein available
Screening programmes close with a data package: primary screen statistics, confirmation data for each hit, counterscreen results and resynthesized material. Library lots ship with composition QC — representation and identity checks by LC-MS or NGS as the format requires.
Service Highlights
- Transwell (MDCK/Boelden-style) transport assays as the default route, with PAMPA-BBB screening held as a proven fallback
- Efflux-ratio analysis worked into the design where the application requires it
- Every reported hit is confirmed by independent resynthesis and re-testing before it reaches you
- Analytical confirmation of every intermediate before the final release
- Library integrity (composition, representation) is measured, not assumed, before screening begins
- BBB permeability report with rank comparison delivered with a complete conjugation or synthesis certificate
How the work runs
Library design
Diversity, degeneracy and deconvolution strategy for Peptide Drugs Blood-brain Barrier Permeability Test Platform are fixed in a design document.
Library synthesis or construction
The library is built with transwell (MDCK/Boelden-style) transport assays and its composition is QC'd before screening.
Primary screening
Screening runs with PAMPA-BBB screening, with controls and statistics defined in advance.
Hit deconvolution
Hits are identified and ranked; counterscreens remove non-specific and promiscuous binders.
Hit confirmation
Every hit is resynthesized and re-tested; only reproducible hits advance.
Hit delivery
Confirmed hits and BBB permeability report with rank comparison are delivered with the full screening data package.
Specifications & timeline
- Turnaround
- 4–8 weeks
- Typical scale
- 10^2 – 10^9 members by format
- Chemistry options
- transwell (MDCK/Boelden-style) transport assays; PAMPA-BBB screening; efflux-ratio analysis
- Deliverable
- BBB permeability report with rank comparison
- QC package
- Library composition QC, screening raw data, hit confirmation package
- Shipping
- Ambient (plates, beads) or dry ice (display libraries)
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.